BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,405,022 | +7.5% | 37,229 | +29.7% | 0.02% | +8.7% |
| Q2 2023 | $1,307,253 | +41.0% | 28,693 | +25.5% | 0.02% | +21.1% |
| Q1 2023 | $927,039 | +292.9% | 22,856 | +393.8% | 0.02% | +216.7% |
| Q4 2022 | $235,940 | -5.2% | 4,629 | 0.0% | 0.01% | -14.3% |
| Q3 2022 | $249,000 | -86.7% | 4,629 | -84.1% | 0.01% | -87.5% |
| Q2 2022 | $1,870,000 | -28.4% | 29,117 | -13.5% | 0.06% | -17.6% |
| Q1 2022 | $2,611,000 | +118.9% | 33,677 | +142.3% | 0.07% | +119.4% |
| Q4 2021 | $1,193,000 | -19.7% | 13,899 | -24.7% | 0.03% | -26.2% |
| Q3 2021 | $1,485,000 | -65.1% | 18,466 | -66.5% | 0.04% | -63.8% |
| Q2 2021 | $4,258,000 | +2.1% | 55,045 | +11.3% | 0.12% | -10.8% |
| Q1 2021 | $4,171,000 | +175.7% | 49,456 | +162.4% | 0.13% | +145.3% |
| Q4 2020 | $1,513,000 | +31.0% | 18,850 | +31.2% | 0.05% | +10.4% |
| Q3 2020 | $1,155,000 | +4177.8% | 14,368 | +4549.8% | 0.05% | +2300.0% |
| Q2 2020 | $27,000 | -77.1% | 309 | -78.7% | 0.00% | -75.0% |
| Q1 2020 | $118,000 | -94.7% | 1,454 | -94.3% | 0.01% | -94.9% |
| Q3 2019 | $2,241,000 | +89.1% | 25,615 | +75.7% | 0.16% | +59.2% |
| Q1 2019 | $1,185,000 | +517.2% | 14,577 | +400.6% | 0.10% | +237.9% |
| Q4 2018 | $192,000 | – | 2,912 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |